Skip to main content

Table 1 Validation of DVH estimation model by applying it to similar cases: dosimetric comparison between the 10 clinical supine VMAT plans and their knowledge-based re-optimizations

From: Applying a RapidPlan model trained on a technique and orientation to another: a feasibility and dosimetric evaluation

  Mean SD 95 % Confidence intervals (%) P
Lower Upper
HI_PGTV Original 0.06 0.01 0.05 0.07 0.01 0.15*
RP-VMAT 0.05 0.01 0.05 0.06
HI_PTV Original 0.26 0.01 0.25 0.27 0 0.62*
RP-VMAT 0.26 0.01 0.25 0.27
CI_PGTV Original 1.01 0.04 0.98 1.04 0.01 0.11
RP-VMAT 1.00 0.04 0.97 1.03
CI_PTV Original 1.03 0.02 1.02 1.05 0.01 0.05*
RP-VMAT 1.02 0.02 1.01 1.04
Dmax Original 53.93 0.35 53.69 54.18 0.36 (0.67 %) 0.07*
RP-VMAT 53.57 0.50 53.22 53.93
D2 % Original 53.37 0.37 53.10 53.63 0.34 (0.64 %) 0.15*
RP-VMAT 53.03 0.46 52.70 53.36
D50 %_UB Original 28.90 5.31 25.10 32.69 5.39 (18.65 %) 0.01
RP-VMAT 23.51 3.26 21.18 25.84
D50 %_FH Original 16.30 1.66 15.11 17.48 2.30 (14.11 %) 0.01
RP-VMAT 14.00 0.92 13.34 14.65
Dmean_UB Original 30.01 4.52 26.77 33.24 4.51 (15.03 %) 0.01
RP-VMAT 25.50 1.54 24.40 26.60
Dmean_FH Original 17.18 1.80 15.90 18.47 1.85 (10.77 %) 0.01
RP-VMAT 15.33 0.68 14.85 15.82
MUs Original 412 41 383 441 18 (4.37 %) 0.14
RP-VMAT 430 23 413 447
  1. Abbreviations: HI homogeneity index, CI conformity index, D max global maximum dose, D 2 % near maximum dose, SD standard deviation, (%) difference between the original and RP-VMAT plans (% relative to the original value), D 50 % dose to the 50 % volume of the structure, D mean mean dose, FH femoral head, UB urinary bladder, MU monitor unit, RP-VMAT volumetric modulated arc therapy plans optimized by RapidPlan. Dose unit (Gy)
  2. *Paired sample T test, otherwise Wilcoxon signed ranks test was used